To determine whether addition of the farnesyltransferase inhibitor tipifarnib ( Zarnestra , R115777 ; Johnson and Johnson Pharmaceutical Research and Development , Beerse , Belgium ) to standard gemcitabine therapy improves overall survival in advanced pancreatic cancer .
